321 / 1241
Standard of care: general agreement
•
Exclusive Radiochemotherapy
•
MMC/5FU (or capecitabine)
•
(CDDP/5FU)
•
No benefit for neoadjuvant chemotherapy
•
No benefit for maintenance
•
IMRT
•
Can reduce acute toxicity
•
High gradient dose between tumor
and normal tissue
•
Needs accurate delineation and control
•
No Gap
•
Good outcomes:
5-year survival=70 %